Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311972 | 0.77 | CA1 (0.41) | CA1CA2 | |
| SCHEMBL1958676 | 0.73 | CA1 (0.41) | CA1CA2 | |
| SCHEMBL4754304 | 0.73 | CA1 (0.41) | CA1CA2 | |
| SCHEMBL1923119 | 0.73 | CA1 (0.46) | CA1CA2 | |
| SCHEMBL4066186 | 0.73 | CA1 (0.41) | CA1CA2 | |
| SCHEMBL9836393 | 0.72 | CYP2A6 (0.36) | CA1CA2 | |
| SCHEMBL853163 | 0.70 | CA1 (0.39) | CA1CA2 | |
| SCHEMBL7190108 | 0.68 | CA1 (0.38) | CA1CA2 | |
| SCHEMBL5022550 | 0.68 | CA1 (0.38) | CA1CA2 | |
| SCHEMBL16289764 | 0.68 | CA1 (0.38) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013162077-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2008146063-A1 | NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT6 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársagág (HU) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | DPYD, TYMP, TST | CA1 2280/4885CA2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.